Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 3/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426961 | 0.93 | MAPK13 (0.39) | CCR8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4426585 | 0.92 | CCR8 (0.37) | CCR8PAK1MAPK14MAPK13MAPK12 | |
| SCHEMBL4428646 | 0.91 | MAPK13 (0.39) | CCR8PAK1MAPK14MAPK13MAPK12 | |
| SCHEMBL4427504 | 0.88 | MAPK13 (0.42) | CCR8PAK1MAPK14MAPK13MAPK12 | |
| SCHEMBL4423515 | 0.88 | MAPK13 (0.41) | CCR8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4429774 | 0.88 | CCR8 (0.35) | CCR8PAK1MAPK14MAPK13MAPK12 | |
| SCHEMBL4437064 | 0.88 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11LCK | |
| SCHEMBL4428635 | 0.87 | MAPK14 (0.37) | CCR8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4437429 | 0.87 | CCR8 (0.35) | CCR8PAK1MAPK14MAPK13MAPK12 | |
| SCHEMBL4426968 | 0.86 | MAPK13 (0.44) | CCR8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656374-B1 | THIAZOLE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | claimed |
| US-7265109-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | claimed |
| EP-1656374-A1 | THIAZOLE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | claimed |
| US-20050038073-A1 | Thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2005-02-17 | — | — | US | claimed |
| WO-2005014593-A1 | THIAZOLE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | claimed |
| EP-1656374-B1 | THIAZOLE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-7265109-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1656374-A1 | THIAZOLE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050038073-A1 | Thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005014593-A1 | THIAZOLE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038073-A1 | Thiazole derivatives | NPY4R, NPY1R, NPY2R | CCR8 3056/4885PAK1 2428/4885MAPK14 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.